Ro 41-5253 |
| رقم الكتالوجGC66433 |
Ro 41-5253 هو أحد مضادات مستقبلات حمض الريتينويك ألفا النشط عن طريق الفم (RARα ؛). يمكن لـ Ro 41-5253 ربط RARα ؛ دون إحداث نسخ أو التأثير على تغيير تغاير RAR / RXR وربط الحمض النووي. Ro 41-5253 يمكن أن يمنع تكاثر الخلايا السرطانية ويحفز موت الخلايا المبرمج ، وله نشاط مضاد للأورام.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 144092-31-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 60 nM (RARα), 2.4 μM (RARβ), 3.3 μM (RARγ)[3].
Ro 41-5253 is an orally active selective retinoic acid receptor alpha (RARα) antagonist. Ro 41-5253 can bind RARα without inducing transcription or affecting RAR/RXR heterodimerization and DNA binding. Ro 41-5253 can inhibit cancer cell proliferation and induce apoptosis, has antitumor activity[1][2].
Ro 41-5253 (1 nM-10 μM, 10 days) significantly inhibits MCF-7 and ZR 75.1 cell proliferation and induces cell apoptosis in a time and dose-dependent manner[1].
Cell Proliferation Assay[1]
| Cell Line: | Human breast-carcinoma lines MCF-7 and ZR 75.1 |
| Concentration: | 1 nM-10 μM |
| Incubation Time: | 10 days |
| Result: | Inhibited 81% MCF-7 cell growth at 10 μM, 30% cell growth at 1 μM and no significant inhibitory effect at concentrations below 0.1 μM. Inhibited 74% ZR 75.1 cell growth at 10 μM, 63% cell growth at 1 μM and 42% cell growth at 0.1 μM. |
Apoptosis Analysis[1]
| Cell Line: | Human breast-carcinoma lines MCF-7 and ZR 75.1 |
| Concentration: | 1 nM-10 μM |
| Incubation Time: | 10 days |
| Result: | Induced 28.5, 21.6, 16 and 12% of MCF-7 cells apoptosis at 10 μM, 1 μM, 0.1 μM and 0.01 μM respectively on the fourth day while induced 58, 51, 36 and 21% of cells apoptosis at 10 μM, 1 μM, 0.1 μM and 0.01 μM respectively after six days. Induced 80, 65, 43 and 29% of ZR 75.1 cells apoptosis at 10 μM, 1 μM, 0.1 μM and 0.01 μM respectively on the sixth day. |
Ro 41-5253 (oral gavage, 10-600 mg/kg, once a week, 4 weeks) can reduce tumor volume in female athymic Balb/mice transplanted with MCF-7 cell line[2].
| Animal Model: | Six-week-old female athymic Balb/mice transplanted with MCF-7 cell line[2] |
| Dosage: | 10, 30, 100, 300 and 600 mg/kg |
| Administration: | Oral gavage; once a week; 4 weeks |
| Result: | Resulted in a reduction in tumor volume at doses of 10, 30 and 100 mg/kg with no toxic side effects. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *